Home › Head and Neck Squamous Cell Carcinoma › District of Columbia
Head and Neck Squamous Cell Carcinoma clinical trials in District of Columbia
9 studies for Head and Neck Squamous Cell Carcinoma are looking for participants at sites in District of Columbia.
Cities in District of Columbia
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- George Washington University Cancer Center, Washington D.C.
RecruitingPhase 3
Ages 60 and older · All sexes · Updated Sep 25, 2026 · NCT04892173Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
- MedStar Washington Hospital Center, Washington D.C.
RecruitingPhase 2
Ages 18 to 79 · All sexes · Updated Sep 22, 2026 · NCT04671667Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors
- Georgetown University Medical Center, Washington D.C.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05983432Radiation Therapy With or Without Cisplatin in Treating Patients With Stage III-IVA Squamous Cell Carcinoma of the Head and Neck Who Have Undergone Surgery
- George Washington University Medical Center, Washington D.C.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Sep 14, 2026 · NCT02734537A Phase 1 Study of NRM-823 in Participants With Locally Advanced or Metastatic Refractory Solid Tumors
- Normunity Investigational Site, Washington D.C.
RecruitingPhase 1
Ages 18 and older · All sexes · Updated Aug 18, 2026 · NCT07182149Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer
- George Washington University Medical Center, Washington D.C.
RecruitingPhase 2
Ages 18 and older · All sexes · Updated Aug 17, 2026 · NCT06532279A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- GSK Investigational Site, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated May 26, 2026 · NCT06256588A Study of Ficlatuzumab in Combination With Cetuximab in Participants With Recurrent or Metastatic (R/M) HPV Negative Head and Neck Squamous Cell Carcinoma
- The George Washington University, Washington D.C.
RecruitingPhase 3
Ages 18 and older · All sexes · Updated Apr 9, 2026 · NCT06064877VMD-928 Monotherapy and in Combination With Pembrolizumab to Treat TrkA Overexpression Driven Solid Tumors or Lymphoma
- The George Washington University Cancer Center (site 212), Washington D.C.
RecruitingPhase 1/2
Ages 18 to 80 · All sexes · Updated Dec 11, 2025 · NCT03556228From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.